New Choices in Targeted Treatments for Advanced or Metastatic Urothelial Carcinoma: Plot Your Own Course Evaluation (ID: i768) Survey

Question Title

* 2. How many years have you been in practice?

≤ 1

1-10

11-20

≥ 21

Question Title

* 3. How many patients with urothelial carcinoma do you see monthly?

1 to 5

6 to 10

11 to 20

≥ 21

I am not directly involved in patient care

Question Title

* 4. Please select the option that best describes your practice setting:

Academic medical center

Community medical center

Other (please specify)

Question Title

* 5. After participating in this activity, how confident are you in the management of patients with urothelial cancer?

Very confident

Confident

Neutral

Little confidence

No confidence

Question Title

* 6. Which of the following describes the impact of this activity on your performance? Please select all that apply.

I better understand the rationale for maintenance therapy in urothelial carcinoma

I am better able to implement new treatment strategies for patients with FGFR mutations or fusions

I am able to utilize clinical trial findings for treatment options after platinum-based chemotherapy and immunotherapy

Question Title

* 7. How committed are you to making changes in your practice based on your participation in this activity?

Very committed

Committed

Neutral

Not committed

I do not plan to make change

Question Title

* 8. What barriers do you see to making changes in your practice? Please select all that apply.

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Constant changing guidelines

Lack of time/resources to consider change

Insurance, reimbursement or legal issues

Other (please explain)

Question Title

* 9. Did you take this activity in Twitter or on integrityce.com?

Twitter

Integrity CE

Question Title

* 10. Did you enjoy the format?

Yes - cool CME

Meh - it was OK

No - waste of time

Question Title

* 11. Tell us why you liked or disliked the format:

Question Title

* 12. After participating in this activity, I am now able to:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Articulate the mechanisms of action of targeted biopharmacologics and immune checkpoint inhibitors (ICIs) used in the treatment of urothelial cancer (UC)	Articulate the mechanisms of action of targeted biopharmacologics and immune checkpoint inhibitors (ICIs) used in the treatment of urothelial cancer (UC) Strongly agree	Articulate the mechanisms of action of targeted biopharmacologics and immune checkpoint inhibitors (ICIs) used in the treatment of urothelial cancer (UC) Agree	Articulate the mechanisms of action of targeted biopharmacologics and immune checkpoint inhibitors (ICIs) used in the treatment of urothelial cancer (UC) Neutral	Articulate the mechanisms of action of targeted biopharmacologics and immune checkpoint inhibitors (ICIs) used in the treatment of urothelial cancer (UC) Disagree	Articulate the mechanisms of action of targeted biopharmacologics and immune checkpoint inhibitors (ICIs) used in the treatment of urothelial cancer (UC) Strongly disagree
Outline efficacy and safety findings from key clinical trials of approved ICIs, antibody-drug conjugates (ADCs), and fibroblast growth factor receptor (FGFR) inhibitors developed for the treatment of advanced or metastatic UC	Outline efficacy and safety findings from key clinical trials of approved ICIs, antibody-drug conjugates (ADCs), and fibroblast growth factor receptor (FGFR) inhibitors developed for the treatment of advanced or metastatic UC Strongly agree	Outline efficacy and safety findings from key clinical trials of approved ICIs, antibody-drug conjugates (ADCs), and fibroblast growth factor receptor (FGFR) inhibitors developed for the treatment of advanced or metastatic UC Agree	Outline efficacy and safety findings from key clinical trials of approved ICIs, antibody-drug conjugates (ADCs), and fibroblast growth factor receptor (FGFR) inhibitors developed for the treatment of advanced or metastatic UC Neutral	Outline efficacy and safety findings from key clinical trials of approved ICIs, antibody-drug conjugates (ADCs), and fibroblast growth factor receptor (FGFR) inhibitors developed for the treatment of advanced or metastatic UC Disagree	Outline efficacy and safety findings from key clinical trials of approved ICIs, antibody-drug conjugates (ADCs), and fibroblast growth factor receptor (FGFR) inhibitors developed for the treatment of advanced or metastatic UC Strongly disagree

Question Title

* 13. The content presented:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Enhanced my current knowledge base	Enhanced my current knowledge base Strongly agree	Enhanced my current knowledge base Agree	Enhanced my current knowledge base Neutral	Enhanced my current knowledge base Disagree	Enhanced my current knowledge base Strongly disagree
Addressed my most pressing questions	Addressed my most pressing questions Strongly agree	Addressed my most pressing questions Agree	Addressed my most pressing questions Neutral	Addressed my most pressing questions Disagree	Addressed my most pressing questions Strongly disagree
Promoted improvements or quality in health care	Promoted improvements or quality in health care Strongly agree	Promoted improvements or quality in health care Agree	Promoted improvements or quality in health care Neutral	Promoted improvements or quality in health care Disagree	Promoted improvements or quality in health care Strongly disagree
Was scientifically rigorous and evidence based	Was scientifically rigorous and evidence based Strongly agree	Was scientifically rigorous and evidence based Agree	Was scientifically rigorous and evidence based Neutral	Was scientifically rigorous and evidence based Disagree	Was scientifically rigorous and evidence based Strongly disagree
Was fair, balanced and free from bias	Was fair, balanced and free from bias Strongly agree	Was fair, balanced and free from bias Agree	Was fair, balanced and free from bias Neutral	Was fair, balanced and free from bias Disagree	Was fair, balanced and free from bias Strongly disagree

Question Title

* 14. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 15. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 16. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for this or related disease state:

Question Title

* 1. What is your degree?

Question Title

* 2. How many years have you been in practice?

Question Title

* 3. How many patients with urothelial carcinoma do you see monthly?

Question Title

* 4. Please select the option that best describes your practice setting:

Question Title

* 5. After participating in this activity, how confident are you in the management of patients with urothelial cancer?

Question Title

* 6. Which of the following describes the impact of this activity on your performance? Please select all that apply.

Question Title

* 7. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 8. What barriers do you see to making changes in your practice? Please select all that apply.

Question Title

* 9. Did you take this activity in Twitter or on integrityce.com?

Question Title

* 10. Did you enjoy the format?

Question Title

* 11. Tell us why you liked or disliked the format:

Question Title

* 12. After participating in this activity, I am now able to:

Question Title

* 13. The content presented:

Question Title

* 14. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 15. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 16. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for this or related disease state: